OncoMatch/Clinical Trials/NCT06114511
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Is NCT06114511 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BL-M07D1 for non-small cell lung cancer.
Treatment: BL-M07D1 — This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) sensitive mutation
Confirmed known HER2-sensitive mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — advanced/metastatic
Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment
Must have received: immunotherapy — advanced/metastatic
Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment
Cannot have received: antibody-drug conjugate containing a camptothecin derivative (topoisomerase I inhibitor)
Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
no severe cardiac dysfunction, left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify